Study is first clinical trial analyzing a targeted therapy specifically developed to treat brain tumors
UCLA-led study of hospitalized patients with Medicare also finds costs are almost equal
UCLA-led study could lead to new strategy for treating aggressive brain cancer
One way scientists can estimate a person’s risk for a wide range of diseases is a measure called a polygenic score.
In 2007, Yale pediatric neurosurgeon Steven Schiff, MD, PhD, visited his friend, Benjamin Warf, MD, at the CURE Children’s Hospital of Uganda.
Breast milk is not simply sustenance. It also is rich in micronutrients that are critical for healthy brain development in infants.
Scientists at Yale have developed a new gene delivery and immune cell engineering technology with the potential to advance cell therapies for cancer and other diseases.
For the past eight years, Dennis Moledina, MD, PhD, assistant professor of medicine (nephrology), has been searching for a new method to determine if a patient with acute kidney injury (AKI) has acute interstitial nephritis (AIN), a common cause of AKI.
Semaglutide, also known by its brand names Ozempic and Wegovy, marks a new era in anti-obesity therapeutics.
African American, Hispanic, and Native American Communities Experience Disparities in PAD Treatment
Two to three weeks after conception, an embryo faces a critical point in its development. In the stage known as gastrulation, the transformation of embryonic cells into specialized cells begins.
Many vascular diseases such as atherosclerosis and pulmonary hypertension are irreversible.
A new Yale-led study finds that liver fibrosis is associated with reduced cognitive function and brain volume, a link mediated, in part, by inflammation.
A Yale Medicine neurologist explains cluster headache and how it differs from migraine and tension-type headaches.
A recent study in JAMA Network Open found that fewer than 1 in 4 people with or at risk for cardiovascular disease (CVD) use wearable devices, and only half of those who wear them do so consistently.
A new study led by George Goshua, MD, MSc, assistant professor of medicine (hematology), examines the cost effectiveness of gene therapy against standard-of-care treatment for patients with sickle cell disease (SCD), using both conventional cost-effective analysis (CEA) and distributional cost-effective analysis (DCEA) methodology, an approach that takes health equity into quantitative consideration.
The increasingly prohibitive cost of prescription medications continues to pose major challenges to the U.S. health care system, leading to poor medication adherence, suboptimal clinical outcomes, and the ever-growing costs of care.
A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery.
From wearable devices to artificial intelligence, the health care world has seen a boom in new digital health technologies.
Around 30% of the global burden of disease is treatable with surgery. But surgeon-scientists receive very little research funding, a new study finds.